How did ibogaine science develop from 1901 to 2026?

Ibogaine science began in 1901, when chemists in France drew pure crystals from the root of an African shrub [1][2]. In 1962, Howard Lotsof's own use tied it to opioid withdrawal [3]. Then came years of care outside medicine, and of US government work [4][5]. Clinics abroad followed, and in 2024 a Stanford study came out in Nature Medicine [6].

What is the history of ibogaine science?

The science of ibogaine runs from a 1901 report to the French Academy of Sciences to a Stanford study in 2024 [1][6]. It falls into five periods. Each began when a new group took up the drug.

- 1901 to 1961. Chemists isolate it, and France sells it as a tonic [1][3]. - 1962 to 1989. Lotsof and a few helpers use it for heroin withdrawal outside medicine, in the US and the Netherlands [3][4]. - 1990 to 1995. Rodent studies look hopeful, and US agencies plan trials [5][7]. - 1996 to 2017. Care moves to clinics abroad; New Zealand lets doctors prescribe it [3][5]. - 2018 to 2026. Hospital studies follow, along with a Stanford paper in Nature Medicine [6][8].

People who read about ibogaine often ask why work on a drug known since 1901 is still at an early stage [9]. Much of the answer lies in this history. What the evidence shows today is set out in Ibogaine: What the Evidence Shows in 2026.

Where does ibogaine come from?

Ibogaine comes from the root bark of iboga, a shrub that grows in Central Africa [2][8]. Iboga is central to Bwiti, a spiritual tradition of Gabon and Cameroon [10]. Indigenous traditions have used plants like iboga for centuries [10].

In Gabon, Bwiti is made up of groups, each with its own rites of passage [11]. In a 2018 field study there, Bwiti followers named iboga as a sacred wood [11]. Large doses are taken in a rite of rebirth that marks entry into the group [5][12]. Small doses of the plant have been used against tiredness, hunger and thirst [5].

Lab science arrived in 1901. That year, scientists in France sent a report on the plant's active compound to the French Academy of Sciences [1]. They made clean white crystals that melted at 152 degrees Celsius. They named the compound ibogine [1].

Their report also cites an earlier note on the plant, by Dybowski and Landrin [1]. A 2026 review dates the start of ibogaine science to this 1901 work [2].

France then turned it into a product. Tablets sold as Lambarene held a small dose, about 5 milligrams [3][12]. A 2018 study dates their sale in France from 1939 to 1970 [3]. They were sold as a boost for nerves and muscles, and as a lift for mood and energy [3][12].

In the 1940s and 1950s, scientists also tested it as a possible drug for the heart and blood vessels [5]. Its use against addiction came later, from people outside the lab [12].

Who discovered that ibogaine helps with opioid withdrawal?

Howard Lotsof linked ibogaine to opioid withdrawal in 1962. He based it on his own use and on reports from people around him [3]. A 2018 study credits the find to people who were treating their own heroin addiction in the 1960s [12].

The finding came from outside medicine. Medicine took three decades to start testing it [3][5].

Lotsof and his co-workers gave ibogaine to people dependent on heroin in the US in 1962 and 1963 [4]. The work picked up again in the Netherlands from 1989 to 1993 [4]. Treatments took place in apartments and hotel rooms. Lay helpers watched each person for two to three days [4].

In a 1999 write-up of these cases, most people's withdrawal signs faded within a day, with no further drug seeking [4].

One woman treated in the Netherlands in 1993 died [4]. That death shaped what came next.

Lotsof got a US patent in 1985 for an oral dose of ibogaine to interrupt heroin addiction, and lab interest followed in the early 1990s [12]. In rodent studies, ibogaine cut how much morphine, heroin, cocaine and alcohol the animals chose to take [7]. It also eased withdrawal signs set off by drugs that block opioid receptors [7].

In 1993, the US Food and Drug Administration approved a trial of ibogaine in people [5]. Early US studies gave only low doses, raising them step by step to test safety [4]. In March 1995, the National Institute on Drug Abuse, known as NIDA, held a review meeting on the drug [4].

NIDA then chose not to fund more human studies [5]. A NIDA official, cited in the 1999 paper, said the 1993 death was a significant factor [4]. A 2015 review adds that drug industry advisers weighed in [5].

In 1995, a team led by Deborah Mash found that the body turns ibogaine into a second active compound, noribogaine [12]. It stays in the blood far longer than ibogaine itself [12][13]. Its story is told in Noribogaine: Pharmacokinetics of the Long Tail.

Why did ibogaine research move outside the United States?

After 1995, most ibogaine care for addiction took place outside normal medicine [5]. A 2015 review ties this to its Schedule I status in the United States [5][6].

The Stanford team behind the 2024 study says such legal limits have held back research [6].

Treatment spread through clinics in other countries. By 1999, a loose network had offered ibogaine for over 30 years [4], and by 2015 dozens of clinics worldwide used it for addiction [5]. In Brazil, a 2014 study of people who took ibogaine with therapy found they went longer without drugs than before [14].

New Zealand took a different path. In 2009, its drug regulator, Medsafe, listed ibogaine as a non-approved medicine [3]. As a result, it can be prescribed legally there [3]. A 2018 study chose New Zealand so that patients could speak freely, with no fear of legal trouble [3].

Lab work on how ibogaine acts went on as well. In a 2005 rat study, ibogaine cut alcohol drinking and raised GDNF in the midbrain [15]. GDNF is a protein that helps some brain cells survive [15]. Blocking it in a reward area of the rats' brains weakened the drop in drinking [15].

Scientists also began to test noribogaine on its own. In 2015 and 2016, one team gave it to healthy men, and then to people coming off methadone [13][16]. In the second group, noribogaine lengthened the heart's QT interval, and more so at higher doses [13]. The QT interval is the time the heart takes to reset its electrical charge between beats.

Over the same years, reports of heart rhythm problems and sudden deaths after ibogaine use kept growing [5]. The longer QT interval has been linked to these sudden deaths [7].

What has ibogaine research found since 2018?

Since 2018, university teams have put out a run of human studies of ibogaine [6][8][12]. Three studies of people dependent on opioids came out that year. They came from St Kitts, Mexico and New Zealand [3][12][17]. In each, withdrawal eased within about three days of treatment [3][12][17].

The St Kitts report came from Deborah Mash's group. The authors wrote that their results confirmed Lotsof's first claims [12]. In New Zealand, drug-use scores also fell sharply over the next twelve months [3].

One person enrolled in the New Zealand study died during treatment [3]. The coroner found the death very likely linked to ibogaine. The most likely cause was a heart rhythm problem [3].

In 2022, a Dutch team gave ibogaine in a hospital to people with opioid use disorder [8]. Their hearts were watched for at least a day. The QT interval grew by about 95 milliseconds. Half the patients passed 500 milliseconds [8]. Screening and constant monitoring lower the risk without removing it [8][12].

In 2024, a Stanford team published a study of ibogaine in Nature Medicine [6]. The men were special forces veterans with brain injuries who took ibogaine with magnesium at a clinic in Mexico [6]. A month later their scores for PTSD, depression, anxiety and disability had all dropped sharply [6]. The study has its own close read in The Stanford MISTIC Study: A Close Read.

In 2026, a Brazilian pilot study in alcohol use disorder found most people said they drank less [18]. The QT interval changed in more than half of those treated [18]. Each study from these years is summed up in Every Major Ibogaine Study, Summarized.

How have people described the ibogaine experience?

People have described ibogaine in much the same way since the 1960s [4][12][19]. It starts with a stream of vivid, dream-like images. A quieter, thoughtful stage follows [4][12].

Lotsof's 1985 patent already spoke of two stages. First came an active phase of visions. Then came a block on withdrawal [12].

The 1999 paper on the early cases gave more detail [4]. The dream-like stage begins half an hour to three hours after the dose and lasts about four to eight hours [4][12]. People see a flood of memories, mostly as pictures, and in these accounts remembered images play a bigger part than hallucinations [4]. A calmer stage of 8 to 20 hours follows, spent thinking over what came up [4].

In the St Kitts series, people often said it felt like a waking dream or like watching a film [12]. About four in ten saw themselves as a child. More than half felt linked to a higher power [12].

The veterans in the 2024 Stanford study wrote about meeting painful memories again [19]. Many met them with love, forgiveness and acceptance [19]. Some felt their sense of self step aside. Some felt sensations in the body that they took as their brain healing [19].

The body has its own part in the story. In the Dutch hospital study, every patient was badly unsteady for a while and could not walk without help [8]. Sleep is often hard for up to three days afterwards [4].

Where the research goes next

The next period turns on trials with a control group. A 2026 review of human research since 1990 found that most good results so far come from open-label and look-back studies [9]. The step still ahead is a double-blind trial that shows a benefit in opioid use disorder [9].

Two trials aimed at that step have finished. Both were randomized and blinded. Both looked at opioid dependence [20][21]. One ran in Spain, in people coming off methadone [20]. The other ran in the UK, in people seeking supervised opioid withdrawal [21]. Neither has put results on the registry yet [20][21].

Texas has written the next step into law. In 2025 it passed Senate Bill 2308 [22]. The law provides for a group with a university, a hospital and a drug developer to run ibogaine trials aimed at FDA approval [22]. The state budget set aside $50 million for it in 2026 [23].

Long-term follow-up is the second path. In a preprint not yet peer reviewed, a twelve-month follow-up of the Stanford veterans reports that their gains held [24].

The third is a safer molecule. In lab tests on human heart cells, man-made relatives of ibogaine did not upset the heart rhythm the way ibogaine does [25]. More on that work is in Beyond Ibogaine: Tabernanthalog and Engineered Analogs.

The fourth is about where the knowledge came from. A 2026 paper says much clinical work on ibogaine has gone ahead without real give and take with the Bwiti people who hold this knowledge, and calls for research questions shaped together and a fair share of the benefits [10]. The rest of the open questions are in Open Questions: What Rigorous Ibogaine Trials Must Answer.

Frequently asked questions

When was ibogaine discovered?

Scientists in France first drew ibogaine out of iboga root bark in 1901 [1][2]. Its link to opioid withdrawal came in 1962, from Howard Lotsof's own use [3]. The plant was part of Central African traditions for centuries before that [10].

Who discovered ibogaine for addiction?

Howard Lotsof is credited with the find, in 1962 [3]. A 2018 study says it was made by people who were treating their own heroin addiction [12]. In 1985, Lotsof got a patent to use it for heroin addiction [12].

Where does ibogaine come from?

Ibogaine comes from the root bark of iboga, a shrub that grows in Central Africa [2][8]. It is the main alkaloid in the root bark [8]. Iboga is at the heart of Bwiti, a spiritual tradition in Gabon and Cameroon [10].

Why is ibogaine illegal in the United States?

In the United States, ibogaine is a Schedule I drug, the class for drugs with no accepted medical use and a high risk of abuse [6]. A 2015 review ties that listing to its image as a hallucinogen and stimulant [5], and the 2024 Stanford team says the status has held back research [6].

Is ibogaine legal in New Zealand?

Yes. In New Zealand, a doctor can legally prescribe ibogaine [3]. In 2009, the drug regulator there, Medsafe, put it on the list of non-approved medicines [3]. A 2018 study of opioid treatment drew its patients from two legal clinics there [3].

What did the Stanford ibogaine research find?

A 2024 Stanford study looked at veterans with brain injuries. They took ibogaine with magnesium at a clinic in Mexico [6]. A month later, their scores had dropped sharply for PTSD, depression, anxiety and disability [6]. The results came out in the journal Nature Medicine [6].